Amneal Pharmaceuticals Q4 Earnings Call Highlights

3 weeks ago 11

MarketBeat

Fri, February 27, 2026 astatine 9:24 AM CST 8 min read

Amneal Pharmaceuticals logo

Strong 2025 results and balance-sheet progress: Amneal reported $3.0B gross (up 8%), adjusted EBITDA of $688M (up 10%) and adjusted EPS of $0.83 (up 43%), portion nett leverage fell to 3.5x and a 2025 refinancing chopped its weighted mean outgo of indebtedness from ~10% to ~6.8%, lowering involvement expense.
Pipeline and portfolio expansion: Management is ramping analyzable generics, injectables and inhalation franchises—including iohexol, a long‑acting risperidone injectable and 2 inhalation approvals—with 59 ANDAs pending (64% complex) and investments successful biosimilars and GLP‑1 manufacturing with Pfizer.
2026 guidance and conception outlook: Company expects $3.05–3.15B revenue, $720–760M adjusted EBITDA and $0.93–1.03 adjusted EPS, forecasting Affordable Medicines maturation of 7–8%, astir level Specialty revenue, and an AvKARE reset to $625–700M earlier resuming maturation successful 2027.
Interested successful Amneal Pharmaceuticals, Inc.? Here are 5 stocks we similar better.

3 Lesser-Known Healthcare Names With Major Upside successful Store

Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting maturation crossed the business, expanding analyzable merchandise launches, and continued concern successful specialty brands, biosimilars, and GLP-1 manufacturing capacity.

Co-CEO Chirag Patel said 2025 was a “defining year” marked by execution and portfolio expansion. Management reported full-year gross grew 8%, adjusted EBITDA accrued 10%, and adjusted EPS roseate 43%, marking what the institution described arsenic its sixth consecutive twelvemonth of growth.

→ SoundHound’s New Sales Assist Agent Put Voice AI Back successful the Spotlight

6 reasons to bargain Teva Pharmaceuticals banal sooner than later

CFO Tassos Konidaris said Amneal exceeded its 2025 fiscal guidance metrics and delivered full-year gross of $3.0 billion. By segment, Affordable Medicines gross grew 4%, Specialty grew 19%, and AvKARE grew 12%. Adjusted gross borderline expanded by 50 ground points to astir 43%, portion adjusted EBITDA grew to $688 cardinal and adjusted EPS roseate to $0.83.

In the 4th quarter, Amneal reported grounds gross of $814 million, up 11% twelvemonth implicit year. Konidaris said Q4 adjusted EBITDA exceeded $175 cardinal (up 13%) and adjusted EPS was $0.21 (up 75%), aided by little involvement disbursal pursuing refinancing completed earlier successful 2025.

→ Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup

Management emphasized advancement connected deleveraging and refinancing. Konidaris said nett leverage declined to 3.5x astatine the extremity of 2025, and the institution generated operating currency travel of $340 cardinal for the year.

Read Entire Article